

1 The exception that proves the rule: Virulence gene expression at the onset of
2 *Plasmodium falciparum* blood stage infections

3
4 Jan Stephan Wichers-Misterek^{1,2,3}, Ralf Krumkamp^{1,4}, Jana Held^{5,6}, Heidrun von Thien^{1,2,3}, Irene
5 Wittmann⁷, Yannick Daniel Höppner^{1,2,3,4}, Julia M. Ruge^{1,2,3,4}, Kara Moser⁸, Antoine Dara⁸, Jan Strauss^{1,2,3,*},
6 Meral Esen^{5,6,9}, Rolf Fendel^{5,6}, Zita Sulyok^{5,6,§}, Peter G. Kremsner^{5,6,10}, B. Kim Lee Sim¹¹, Stephen L.
7 Hoffman¹¹, Michael F. Duffy¹², Thomas D. Otto¹³, Tim-Wolf Gilberger^{1,2,3}, Joana C. Silva⁸, Benjamin
8 Mordmüller^{5,6,#}, Michaela Petter^{7,12}, Anna Bachmann^{1,2,3,4}

9
10 ¹ Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany

11 ² Centre for Structural Systems Biology, Hamburg, Germany, Notkestraße 85, 22607 Hamburg, Germany

12 ³ Biology Department, University of Hamburg, Hamburg, Germany

13 ⁴ German Center for Infection Research (DZIF), partner site Hamburg-Borstel-Lübeck-Riems, Germany

14 ⁵ Institute of Tropical Medicine, University of Tübingen, Wilhelmstraße 27, 72074 Tübingen, Germany

15 ⁶ German Center for Infection Research (DZIF), partner site Tübingen, Germany

16 ⁷ Institute of Microbiology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Wasserturmstraße
17 3/5, 91054 Erlangen, Germany

18 ⁸ Institute for Genome Sciences, University of Maryland, School of Medicine, 670 W. Baltimore St., Baltimore, MD 21201, USA

19 ⁹ Cluster of Excellence: EXC 2124: Controlling Microbes to Fight Infection, Tübingen, Germany

20 ¹⁰ Centre de Recherches Médicales de Lambaréné, BP242 Lambaréné, Gabon

21 ¹¹ Sanaria Inc., 9800 Medical Center Drive, Rockville, MD 20850, USA

22 ¹² University of Melbourne, Melbourne/Parkville VIC 3052, Australia

23 ¹³ School of Infection & Immunity, University of Glasgow, Glasgow G12 8TA, UK

24 * present address: GEOMAR Helmholtz Centre for Ocean Research Kiel, 24105 Kiel, Germany

25 § present address: University Children's Hospital Tübingen, 72076 Tübingen, Germany

26 # present address: Radboud University Medical Center, Radboud Institute of Molecular Life Sciences, Department of Medical
27 Microbiology, Postbus 9101, 6500 HB Nijmegen, The Netherlands

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 Corresponding author: bachmann@bnitm.de

29

30 Abstract

31 Controlled human malaria infections (CHMI) are a valuable tool to study parasite gene expression *in vivo*
32 under defined conditions. In previous studies, virulence gene expression was analyzed in samples from
33 volunteers infected with the *Plasmodium falciparum* (Pf) NF54 isolate, which is of African origin. Here,
34 we provide an in-depth investigation of parasite virulence gene expression in malaria-naïve European
35 volunteers undergoing CHMI with the genetically distinct Pf 7G8 clone, originating in Brazil. Differential
36 expression of *var* genes, encoding major virulence factors of Pf, PfEMP1s, was assessed in *ex vivo*
37 parasite samples as well as in parasites from the *in vitro* cell bank culture that was used to generate the
38 sporozoites (SPZ) for CHMI (Sanaria® PfSPZ Challenge (7G8)). We report broad activation of mainly B-
39 type subtelomeric located *var* genes at the onset of a 7G8 blood stage infection in naïve volunteers,
40 mirroring the NF54 expression study and suggesting that the expression of virulence-associated genes
41 is generally reset during transmission from the mosquito to the human host. However, in 7G8 parasites,
42 we additionally detected a continuously expressed single C-type variant, Pf7G8_040025600, that was
43 most highly expressed in both pre-mosquito cell bank and volunteer samples, suggesting that 7G8,
44 unlike NF54, maintains expression of some previously expressed *var* variants during transmission. This
45 suggests that in a new host, the parasite may preferentially express the variants that previously allowed
46 successful infection and transmission.

47

48 Introduction

49 Malaria caused by *Plasmodium falciparum* (Pf) remains one of the most serious global health problems,
50 especially among children under the age of five. The clinical symptoms of malaria are exclusively
51 associated with the erythrocytic stage of the parasite lifecycle, and virulence has been linked to the
52 variant surface antigen Pf erythrocyte membrane protein 1 (PfEMP1) ¹. This immunodominant surface
53 antigen is encoded by approximately 60 different *var* genes that differ in the composition of their
54 adhesive extracellular protein domains, chromosomal location, and transcriptional orientation ²⁻⁴.
55 Group B *var* genes include the most telomeric genes on most of the 14 Pf chromosomes adjacent to

56 group A *var* genes. A few group B *var* genes are also present in central chromosomal clusters along with
57 group C *var* genes. The proteins encoded by group A are longer and more complex in domain
58 composition than those of the other *var* gene groups⁵. Group A and B *var* genes, particularly those
59 containing an EPCR-binding CIDR α 1 domain, are more frequently associated with severe disease and
60 complications in paediatric infections⁶⁻¹¹. Group C *var* genes have been associated with mild malaria¹²,
61 and a single, highly conserved, subtelomeric, group E *var* gene encodes the VAR2CSA protein, which is
62 strongly associated with placental malaria¹³. A few other variants (*var1*, *var3*) are also conserved in
63 various Pf isolates, but their biological function is still unknown. Although the total number of *var* genes
64 varies among Pf isolates, the proportion within each subgroup is relatively constant⁵. Recently,
65 comparison of 15 genomes from geographically dispersed Pf isolates revealed that the highly
66 polymorphic variable gene families exhibit little sequence homology, some copy number variation, but
67 considerable consistency in their genomic organisation such as the orientation of the most telomeric
68 *var* gene, positional conservation, and a fairly consistent number of *var* genes in internal clusters with
69 similar orientation¹⁴.

70 *Var* gene expression is monoallelic, i.e. each parasite expresses only a single variant at a given time¹⁵.
71 Many factors have been found to contribute to the regulation of *var* gene expression, e.g., cis-acting
72 elements such as the *var* promoter and intron^{16,17}, trans-factors^{18,19}, higher order chromatin structures
73^{20,21}, and epigenetic marks²²⁻²⁶. The majority of *var* genes is repressed in a heterochromatin
74 environment characterized by the histone modification histone 3 lysine 9 trimethylation (H3K9me3),
75 which is bound by heterochromatin protein 1 (HP1)²⁷⁻²⁹. The single active *var* gene is largely free of
76 H3K9me3 and instead assumes a euchromatic structure with promoter enrichment of the histone
77 variants H2A.Z and H2B.Z and histone acetylations including H3K9ac and H3K27ac^{22,24,25,30}.
78 Nevertheless, a comprehensive mechanistic understanding of how the mutually exclusive regulation of
79 *var* expression occurs does not exist. Previous experiments examining switch rates in clonal cell lines
80 showed that subtelomeric *var* genes have higher switch rates than central *var* genes, with A-type *var*
81 genes rarely activated in *in vitro* cultures and so are not detected without selection pressure.
82 Mathematical modeling supports the idea of a non-random, highly structured switch pathway in which

83 an originally dominant transcript switches either to a new dominant transcript or back to the previous
84 one via a set of switch intermediates³¹. The *var2csa* gene of group E was previously proposed to be one
85 such intermediate^{32,33}. Therefore, switching of *var* gene expression is determined by intrinsic
86 activation/deactivation rates of *var* genes, suggesting that the frequency of antigenic variation is a
87 balanced process between hierarchical *var* switches and selective forces in the host, such as host
88 genetics and immunity.

89 Controlled human malaria infections (CHMI) provide a tailored environment to study parasites *var* gene
90 expression *in vivo* under defined conditions, e.g., variables such as host immunity and infection time
91 (i.e., the number of replication cycles of the parasite) can be monitored or even controlled. Previous
92 results with the Pf isolate NF54 indicate that at some point during host-to-host transmission, the *var*
93 expression profile is reset, allowing a phenotypically diverse population of parasites expressing different
94 subtelomeric B-type *var* genes to enter the blood^{34,35}. These results are consistent with observations in
95 a murine malaria model, in which mosquito transmission of serially blood-passaged parasites resulted
96 in broad activation of subtelomeric genes encoding variant surface antigens³⁶. How this reset is
97 achieved at the molecular level is currently also unknown.

98 In the past, the NF54 isolate was commonly used for CHMI, but recently other strains have become
99 available for heterologous CHMI: 7G8 from Brazil, NF166.C8 from Guinea, and NF135.C10 from
100 Cambodia. All of these strains have been shown to be representative of their geographic origin and to
101 differ in their genome structure, sequence, and immunogenic potential^{37,38}. The NF54 isolate was
102 isolated from a Dutch patient who lived near Schiphol Airport, Amsterdam, and had never left the
103 Netherlands. The infected mosquito responsible for this airport malaria case was probably imported
104 from Africa³⁹. In contrast, 7G8 was cloned from the IMTM22 isolate in 1984 and selected for its ability
105 to produce microgametes, exflagellate, and infect *Anopheles freeborni* resulting in oocysts and
106 sporozoites⁴⁰.

107 In the present study we show the first *in vivo* data on *var* gene expression from CHMI with malaria-naïve
108 volunteers infected with the Pf clone 7G8 and provide new insights into the *var* gene expression pattern
109 that Pf uses to establish a blood stage infection after transmission from one human host to another.

110

111 Results

112

113 The 7G8 *var* gene repertoire and the domain composition of the encoded PfEMP1 variants

114 In total, the 44 *var* genes of the 7G8 clone longer than 6 kb were analyzed in this study (Table S1). An
115 additional 24 short *var* gene pseudogenes and fragments are annotated in PlasmoDB Release 58 (23.
116 June 2022) ⁴¹. To account for this, we also included a single C-type pseudogene (Pf7G8_120024200)
117 (Table S1) ¹⁴.

118 The Pf clone 7G8 encodes six group A *var* genes, including two *var1* variants (IT- and 3D7-type ⁴²), 28
119 group B *var* genes, ten group C *var* genes (including the Pf7G8_120024200 pseudogene) and one group
120 E *var2csa* gene (Table S1, Figure 1A) ^{14,37}. Genes of the conserved *var3* subfamily are absent. Two *var* A
121 genes encode CIDR α 1 domains that presumably can bind EPCR, and the other two A-type variants have
122 a N-terminal head structure with CIDR δ/γ domains of unknown binding capacity. All remaining B- and
123 C-type *var* genes encode PfEMP1 with CIDR α 2-6 domains responsible for binding the host's CD36
124 receptor. In total, 24 genes of type A, B or E are located in subtelomeric regions (24/44=54.6%), although
125 it is unclear on which chromosome the *var* gene Pf7G8_000005200 is located. Three pseudogene
126 annotations larger than 6 kb can be found on PlasmoDB: the *var1* copy (3D7-type), the group E *var2csa*
127 gene and the B-type gene Pf7G8_060005400. All contain a premature stop codon in the ATS sequence
128 (Table S1).

129

130 *In vitro var* transcript profiles of cell bank 7G8 parasites at ring stage prior to mosquito passage

131 Based on the newly assembled and annotated 7G8 *var* gene set, we designed and validated gene-
132 specific primer pairs for each *var* gene (Table S2). Subsequent qPCR and RNA-seq analysis was
133 performed side-by-side using RNA from ring-stage parasites prior to mosquito infection (Sanaria cell
134 bank, aliquot B, generation 13). The Bland-Altman-Plot of the expression values shows high similarity
135 between the two data sets with only three outliers, Pf7G8_020026900 (A, *var1-IT*), Pf7G8_050037900
136 (A, *var1-3D7*) and Pf7G8_060022500 (B-type) (Figure 1B–D).

137 In addition, we performed comparative qPCR analysis of two cell bank aliquots A and B to probe into
138 putative variations within the parasite population used for sporozoite production. We showed that the
139 *var* gene expression pattern in both aliquots is dominated by a centromeric group C *var* gene variant,
140 Pf7G8_040025600, which accounts for 30.3% (aliquot A, generation +12 after thawing) and 43.3%
141 (aliquot B, generation +6 after thawing) of the total *var* gene transcripts, followed by a second
142 centromeric type C *var* gene, Pf7G8_080014200 (aliquot A: 25.2%; aliquot B: 14.9%), and the group E
143 *var2csa* gene, Pf7G8_120005700 (aliquot A: 10.8%; aliquot B: 4.5 %) (Figure 2A, B, Table S3). This
144 specific expression pattern was revalidated in both cell bank aliquots after additional *in vitro*
145 proliferation cycles (aliquot A: +15, +24; aliquot B: +13, +19). It was found that the overall pattern of *var*
146 gene expression among each aliquot remained similar over time, though Pf7G8_040025600 expression
147 declined in aliquot A at the last time point (Figure 2A, Table S3).

148

149 ***In vivo var* transcript profiles in malaria-naïve volunteers infected with 7G8 sporozoites**

150 Next, we analyzed the *var* gene expression profiles in samples from 7G8-infected volunteers from two
151 different clinical trials, MAVACHE⁴³ and CVac-Tü3⁴⁴ (Figure S1). Our analysis of *var* gene expression
152 profiles in parasites from eleven individual malaria-naïve volunteers (Table 1) showed that transcripts
153 of all 45 *var* gene variants were detectable during the early blood stage 7G8 infection, similar to the
154 expression pattern previously observed in NF54³⁵. Interestingly, all volunteer samples showed a very
155 similar *var* gene expression pattern (Figure 2A, C, D, E) dominated by the same single centromeric group
156 C *var* gene variant, Pf7G8_040025600, accounting for a median 41.0% (IQR: 37.7–49.4) of total *var* gene
157 expression (Table S3). In addition, a broad induction of subtelomeric *var* genes, mainly group B, was
158 observed (Figure 2A, C, D). Besides the dominant Pf7G8_040025600, the next ten most highly expressed
159 *var* variants, each accounting for more than 2% of total *var* gene expression, are classified as B-type,
160 and nine of them are located in subtelomeric regions (Figure S2, Table S3). Hierarchical cluster analysis
161 and pairwise Pearson correlation coefficients of samples from pre-mosquito cell bank parasites and
162 malaria-naïve infected volunteers showed clearly distinct expression profiles except for the dominant
163 C-type Pf7G8_040025600 highly expressed in both (Figure 2A, E). Consistent with this, a comparison of

164 expression levels between subtelomerically located *var* genes in parasites from malaria-naïve
165 volunteers and pre-mosquito cell bank parasites revealed a significant difference between both gene
166 subsets, while a comparison of only centromeric *var* gene expression revealed no significant difference
167 (Figure 2F). In general, significantly higher expression of subtelomerically located genes compared to
168 centromeric genes was observed *in vivo*.

169

170 **Characterization of dominant C-type *var* gene expressing parasites**

171 All 11 samples from 7G8-infected volunteers analyzed in this study had the same *var* expression
172 signature: The C-type *var* gene Pf7G8_040025600 was the dominant transcript that did not appear to
173 be reset during transmission. This might suggest that this gene in 7G8 is mis-regulated in a way that it
174 is either i) permanently activated, or ii) escapes from the mutually exclusive epigenetic silencing
175 machinery, or iii) not subject to resetting during transmission^{34,35}. Pf7G8_040025600 is the only *var*
176 gene present in a central cluster of variant surface antigen genes on chromosome 4, where most other
177 Pf strains have multiple *var* genes¹⁴, and which also includes a *ruf6* sequence, a *rif* gene, and a *var*
178 pseudogene. To probe into the first hypothesis, we re-evaluated the RNA-seq transcriptome data from
179 the pre-mosquito cell bank parasites (aliquot B) but found no apparent activation of the other genes
180 near Pf7G8_040025600. Some smaller non-coding transcripts were expressed at low level from
181 upstream of this locus, including a *ruf6* sequence known to positively regulate neighboring *var* genes⁴⁵
182 (Figure 3A).

183 Second, to ensure that Pf7G8_040025600 expression did not exhibit an aberrant expression profile
184 during asexual blood stage development, we tightly synchronized 7G8 parasites from the cell bank and
185 performed qPCR on ring and schizont stage parasites. The data showed that Pf7G8_040025600
186 expression, as well as expression of all other minor *var* transcripts, was downregulated upon parasite
187 maturation, as expected: Schizonts showed a 22-fold reduction in relative expression compared to ring
188 stage parasites (relative expression values of 36,357.1 in rings and 1,659.1 in schizonts) (Figure 3B).

189 Third, to test if Pf7G8_040025600 escaped mutually exclusive expression, we panned pre-mosquito cell
190 bank parasites (aliquot A) on recombinant CSA, allowing selection of parasites expressing the CSA-

191 binding PfEMP1 variant encoded by the *var2csa* gene⁴⁶. In parallel, an aliquot of 7G8 parasites obtained
192 from BEI Resources (MRA-152) was subjected to the same procedure as a control for CSA binding.
193 Immediately prior to selection on CSA, the pre-mosquito cell bank parasites expressed
194 Pf7G8_040025600 (48.7%), Pf7G8_080014200 (17.5%) and the *var2csa* Pf7G8_120005700 at a much
195 lower level (7.0%). In 7G8 MRA-152 parasites, the *var2csa* gene Pf7G8_120005700 clearly dominated
196 the expression pattern even without any selection on CSA (96.2%), which was also the case in the two
197 other 7G8 lines deposited at BEI Resources by different providers (MRA-154: 97.9%; MRA-926: 74.6%)
198 (Figure S3). After three rounds of selection, both 7G8 lines expressed the *var2csa* gene
199 Pf7G8_120005700 almost exclusively (cell bank aliquot A: 99.2%; MRA-152: 98.9%) (Figure 3C, D; Table
200 S4). The conserved *var2csa* gene is known to encode the ligand for CSA⁴⁶, although it was annotated as
201 a protein-coding pseudogene in 7G8 on PlasmoDB Release 58 (23. June 2022) due to a premature stop
202 codon at position 8,622 bp resulting in a truncated ATS sequence lacking the terminal 220 amino acids
203 (Table S1). However, in agreement with recent reports, our data suggest that the 7G8 *var2csa* gene
204 encodes a fully functional protein that is exported to the host cell surface and can bind CSA *in vitro*^{47,48}.
205 Fourth, another explanation for the high expression of the C-type gene Pf7G8_040025600 in pre-
206 mosquito cell bank parasites as well as in parasites infecting the volunteers could be a very strong
207 promoter or preference of the 7G8 strain used for CHMI to switch to Pf7G8_040025600 expression.
208 This was investigated by cultivating the CSA-selected cell bank parasite aliquot A for an additional 100
209 parasite replication cycles. At every 10th parasite generation, the *var* gene expression pattern was
210 analyzed by qPCR, which was surprisingly stable over time with almost exclusive expression of the
211 *var2csa* gene (Figure S4, Table S4). The expression of Pf7G8_040025600 was rather low, with a median
212 relative expression value of 189.3 (IQR: 61.1–303.1) compared to the median *var2csa* expression value
213 of 357,486.3 (IQR: 260,004.0–563,871.6). These data indicate that predominant or frequent switching
214 to Pf7G8_040025600 expression in the 7G8 strain used is unlikely to be a major factor in upregulated
215 expression of this gene in pre- and post-mosquito samples.
216 So far, all these data supported normal regulation of the Pf7G8_040025600 gene. However, because
217 analyses at the parasite population level could miss individual variations in single parasite clones, we

218 produced 13 clones from the cell bank aliquot A after 36 *in vitro* replication cycles by limiting dilution.
219 The expression pattern of *var* genes was determined by qPCR, and eight clones were selected for further
220 comparison: five of the clonal cell lines showed distinct expression of Pf7G8_040025600 (A1E4, A1G5,
221 A2E10, A2F10, A2G2), while three cell lines dominantly expressing other *var* genes of type C (A1F4:
222 Pf7G8_120024200, A1F11: Pf7G8_080014200) or E (A1G9: Pf7G8_120005700/*var2csa*) were chosen as
223 controls (Figure 3C, D). These *var* expression patterns further confirm that the mechanism of mutually
224 exclusive expression regulation in Pf7G8_040025600-expressing cell lines is still intact. Moreover, the
225 successful selection of subclones for CSA binding revealed that *var* gene expression is not permanently
226 fixed to this variant but can still switch to *var2csa*, which was confirmed at the RNA and protein levels
227 (Figure 3C, D). The presence of all *var* genes on gDNA level in each subclone was verified by qPCR (Figure
228 S5).

229 To identify genomic alterations in 7G8 cell bank subclones possibly associated with persistent
230 expression of Pf7G8_040025600 after transmission, the subclones A2E10, A2G2 (both expressing
231 Pf7G8_040025600), and A1G9 (control) were subjected to whole genome sequencing. After stringent
232 filtering, both Pf7G8_040025600-expressing clones had mutations of A to G at position 886709 on
233 chromosome 11, which is located in the intron of the ERO1-encoding gene Pf7G8_110027600 (putative
234 endoplasmic reticulum oxidoreductin), and at position 679487 on chromosome 12 within the coding
235 region of gene Pf7G8_120022100 (putative sno-RNA-associated small subunit rRNA processing protein),
236 reflecting a synonymous exchange. Clone A2G2 had two additional single nucleotide mutations on
237 chromosome 10 at positions 1015567 (C->T, nonsynonymous) and 1015545 (T->C, synonymous), both
238 within Pf7G8_100029900, which encodes a conserved membrane protein of unknown function. Overall,
239 whole genome sequencing revealed no nonsynonymous changes between the subclones expressing the
240 Pf7G8_040025600 gene and the *var2csa*-expressing control (Table S5), making it unlikely that genetic
241 differences between the two subpopulations cause reset failure.

242 Finally, to exclude epigenetic differences in gene regulation, we also performed ChIP-qPCR using ring
243 stages from the cell bank aliquot A (bulk culture) and the same parasite line enriched for CSA-binding,
244 as well as the cell bank subclones A2E10 (expressing Pf7G8_040025600) and A1G9 (*var2csa*-expressing

245 control) (Figure 4, Table S6). Several epigenetic marks typically involved in *var* gene regulation were
246 inspected, including the heterochromatin mark H3K9me3, which is associated with silent *var* genes²²,
247 the euchromatic mark H3K27ac, which is typically enriched in active *var* promoters³⁰, and the histone
248 variant H2A.Z, which occupies active *var* promoters as well as *var* introns regardless of expression status
249²⁴. Both, the CSA-enriched cell bank culture and the A1G9 subclone showed the expected epigenetic
250 profile at their expressed *var2csa*-loci (low H3K9me3, high H3K27ac/H2A.Z) and the silenced
251 Pf7G8_040025600 locus (high H3K9me3, low H3K27ac/H2A.Z). However, this was less obvious in
252 unselected cell bank parasites as well as the A2E10 subclone with dominant Pf7G8_040025600
253 expression. The Pf7G8_040025600 gene was clearly heterochromatic at a similar level as the *var2csa*
254 gene, and was only marginally enriched for activation marks at the promoter (H2A.Z, H3K27ac) (Figure
255 4B, C). However, at least a slight reduction of H3K9me3 in Pf7G8_040025600 expressing relative to
256 *var2csa* expressing cultures was consistently observed at the Pf7G8_040025600 gene, indicating that
257 the locus may be partially unpacked from heterochromatin in part of the population. Parallel RNA
258 analysis revealed that selection of parasites on CSA indeed resulted in a homogenous population with
259 very high *var2csa* expression, whereas the unselected cell bank parasites and the A2E10 subclone
260 showed a more diverse pattern of *var* expression with lower levels of total *var* expression and
261 Pf7G8_040025600 in particular, which may possibly explain the differences in signal intensity of the
262 epigenetic marks (Figure 4D).

263 Overall, we demonstrated that expression of the C-type gene Pf7G8_040025600 (i) is a unique feature
264 of parasites from the Sanaria cell bank, (ii) is correctly regulated across asexual blood stages, (iii) occurs
265 in a mutually exclusive manner, and (iv) parasites are neither fixed to nor tend to preferentially activate
266 expression of this variant after selection for *var2csa* expression. Moreover, parasites expressing this *var*
267 variant share the genomic and epigenetic background with parasites expressing other *var* variants,
268 which further rules out the presence of two distinct 7G8 parasite populations in the original cell bank
269 aliquots, with one population behaving like NF54 and resetting *var* gene expression during mosquito
270 passage, and the other population having lost its ability to reset *var* expression and being fixed to
271 express Pf7G8_040025600. Therefore, our data rather support the second hypothesis, namely that

272 Pf7G8_040025600 is not subject to resetting during transmission, suggesting that epigenetic resetting
273 of *var* genes can be incomplete during passage through mosquitoes, possibly through the
274 semiconservative retention of histone modifications at replicated *var* loci during meiosis.

275

276 Discussion

277 After transmission, parasites are faced with a new environment defined by various parameters such as
278 the metabolic state of the host, pre-existing immunity, drug pressure, pregnancy or other infections.

279 One way to cope with these alterations might be to epigenetically reset genes upon transmission to

280 create a diverse population of parasites expressing different *var* genes from which clones best adapted

281 to the new environment can expand. This "bet-hedging" strategy, which is a viable alternative to

282 directed transcriptional responses, is thought to be key to adaptations to general variations in the

283 environment⁴⁹. This has been shown, for example, for expression of *var* genes after liver release of

284 NF54 parasites in CHMI of immunologically naïve individuals^{34,35,50,51}. There, expression of *var* genes at

285 the onset of infection shows a broad activation pattern of many group B subtelomeric genes and certain

286 group A variants. This broad expression repertoire is reduced in NF54 parasites from infected volunteers

287 with a higher degree of pre-existing immunity. In these individuals, only a single or very few *var* gene

288 variants are highly expressed, presumably encoding PfEMP1 which are not recognized by the host

289 immune system³³. Intriguingly, the *var* gene expression profile changed dramatically during mosquito

290 passage of NF54 Pf parasites from the monoallelic *var2csa* expression in the initial culture used for

291 gametocytogenesis and sporozoite production to the broad pattern of subtelomeric *var* gene

292 transcription in the infected volunteers^{35,51,52}.

293 In this study, we investigated whether the observations using NF54 parasites also hold true in other Pf

294 isolates, or whether parasite strain-specific differences in *var* gene expression patterns can be observed.

295 This is of particular importance because current vaccination concepts using whole parasites – either

296 radiation-attenuated sporozoites (PfSPZ Vaccine) or sporozoites co-administered with

297 chemoprophylaxis (PfSPZ-CVac) – are based on the strain NF54. For the first time, we have obtained

298 expression data for the entire *var* gene repertoire in another parasite strain, 7G8, which originates from

299 a different geographic region and is genetically distinct from NF54^{37,38}. When 7G8 parasites were used
300 for CHMI, a very similar pattern of *var* gene group B activation was observed in naïve volunteers. This
301 suggests that Pf generally preferentially activates subtelomeric *var* genes after release from the liver,
302 while central *var* genes tend to remain silent³⁵, allowing a phenotypically diverse population of parasites
303 expressing different subtelomeric *var* genes to enter the blood from the liver. These results are
304 consistent with observations in a mouse malaria model, where transmission of serially blood-passaged
305 parasites by mosquitoes resulted in broad activation of subtelomeric genes encoding variant surface
306 antigens³⁶. How this switch occurs at the molecular level is currently unknown, but there is strong
307 evidence that the regulation of *var* genes in Pf relies on epigenetic mechanisms⁵²⁻⁵⁴.

308 The broad activation pattern of many *var* genes seems to contradict the concept of safeguarding the
309 antigenic repertoire. However, this strategy of releasing a parasite population from the liver that
310 expresses PfEMP1 proteins with diverse adhesive properties would allow optimal and rapid adaptation
311 to a new host environment shaped by selective forces such as host genetics and pre-existing immunity.
312 At the same time, maintaining a repertoire of *var* gene variants silenced after liver release would
313 prevent the parasites from exposing their entire antigenic repertoire too early. Differences in intrinsic
314 switching rates of individual *var* genes would then lead to the expansion of parasite populations that
315 express dominant PfEMP1 variants during the course of infection and are further selected by immunity,
316 consistent with the fashion observed in chronic infections.

317 Interestingly, the dominant C-type *var* gene Pf7G8_040025600 in our study escapes from resetting
318 during transmission. There are at least five possible explanations for the high expression of this variant
319 in pre-mosquito parasites and *in vivo* during infection of volunteers: (i) the gene might have escaped
320 mutually exclusive expression, (ii) Pf7G8_040025600 might be generally deregulated during asexual
321 blood stage development, (iii) a subpopulation of parasites might have a mutation or carry epigenetic
322 marks making this variant resistant to the resetting mechanism during mosquito passage, (iv) this *var*
323 gene variant could have a very active promoter that allows high expression levels under different
324 conditions, or (v) only parasites expressing *var2csa* or other *var* gene variants that act as switching hubs
325 are able to reset their *var* gene expression during transmission. We tested most of these hypotheses

326 and demonstrated that Pf7G8_040025600 expression is mutually exclusive with that of other *var* genes,
327 and the gene is correctly repressed in schizonts, does not have a higher on switch rate than other *var*
328 gene variants, and none of the few genetic differences observed between clonal Pf7G8_040025600-
329 and *var2csa*-expressing parasites can explain the phenotype. Moreover, these parasites were still able
330 to switch their *var* expression to a different variant, consistent with the successful generation of 7G8
331 sporozoites by Sanaria, suggesting that the switch from asexual replication to gametocytogenesis is also
332 not hindered in these parasites. Our results from ChIP-qPCR also suggest that epigenetic regulation of
333 Pf7G8_040025600 is not affected, as the gene is normally silenced by heterochromatin. The absence of
334 detection of activating histone marks may be explained by the mixed *var* expression pattern in about
335 half of the population, as it is known that in parasite populations with heterogeneous *var* gene
336 expression, signals from ChIP-qPCR or -seq can be leveled out ^{51,55}.
337 Based on our data, we hypothesize that *var* gene expression may partly underlie epigenetic imprinting
338 during transmission from one human host to another, which is thought to depend on the ability of each
339 *var* gene locus to establish and maintain heterochromatin. Consistent with other studies showing that
340 C-type *var* genes are turned on less frequently but can dominate expression patterns by slow silencing
341 ^{56,57}, C-type *var* genes may be less effective at re-establishing heterochromatin during transmission, in
342 line with their location in central chromosomal regions with likely fewer Sir2A-dependent silencing
343 nucleation sequences. In conjunction with the intrinsic promoter activity of each *var* gene variant, Pf
344 could exhibit a loose activation hierarchy of subtelomeric *var* genes upon entry into the human blood
345 phase. This strategy would allow the parasite population to explore a new host environment by
346 expressing many different PfEMP1 variants as well as testing the previously successful variant in a
347 different host, adding another layer to the parasite's survival or adaptive strategies in humans. Although
348 purely speculative, this could also explain why some parasite strains cause more severe disease courses
349 than others. However, since *var2csa* is also discussed as a switching intermediate ³¹⁻³³, it is possible that
350 resetting is also coordinated via intermediate *var2csa* expression, from which parasites can express *var*
351 genes at the onset of the blood phase with probabilities based on intrinsic on-rates for each variant. It
352 should be noted that truncation of VAR2CSA-ATS in 7G8 parasites could also affect the efficiency of

353 these processes. Further studies, such as CHMIs with NF54 parasites or other strains expressing
354 different *var* gene variants prior to transmission, or with parasites with genetically modified *var2csa*
355 locus, are needed to evaluate these hypotheses.

356 In summary, we demonstrated that (i) expression of subtelomeric B-type *var* genes is induced in 7G8
357 parasites at the onset of blood stage infection in malaria-naïve individuals, (ii) cell bank parasites used
358 for PfSPZ production and isolated from volunteers exhibit an expression pattern dominated by a single
359 C-type variant, Pf7G8_040025600, suggesting that this C-type variant underlies epigenetic memory
360 during mosquito passage. Our results from two genetically distant parasite backgrounds show that
361 expression of virulence-associated genes in Pf is, at least partially, reset to subtelomeric B-type
362 expression during transmission from mosquito to human host, but also provide evidence for an
363 alternative strategy of the parasite in which infection in the next host is established by maintenance of
364 expression of a previously successful PfEMP1 variant in part of the parasite population. This suggests
365 that the PfEMP1 variant expressed in the previous malaria patient is an important factor that could
366 determine the pathophysiology of the subsequent infection. In conclusion, the NF54 strain and its clone
367 3D7 appear to be an accurate reference for the entire species in terms of gene content and organization,
368 as previously noted by Otto et al.¹⁴, but there appear to be differences among Pf isolates in resetting
369 *var* gene expression during transmission to establish infection in another human host^{34,35}.

370

371 **Methods**

372

373 **Ethics**

374 The ethics committee of the University Clinic and the Medical Faculty of the University of Tübingen
375 approved both studies, MAVACHE and CVac-Tü3, of which samples were examined in this work, and the
376 U.S. Food and Drug Administration Agency (FDA) provided regulatory oversight. The studies were
377 conducted according to the principles of the Declaration of Helsinki in its 6th revision and the guidelines
378 of the International Conference on Harmonization–Good Clinical Practice (ICH-GCP). For the MAVACHE

379 study, the registration code at ClinicalTrials.gov is NCT02704533; the CVac-Tü3 trial is registered with
380 the EU Clinical Trial Register under 2018-004523-36. All volunteers provided written informed consent,
381 and understanding of the study and procedures was assessed with a quiz.

382

383 **CHMI trials and blood sampling**

384 Samples were collected during different phases of the MAVACHE⁴³ and CVac-Tü3 trials⁴⁴. Both trials
385 were conducted at the Institute of Tropical Medicine in Tübingen, Germany, where healthy, malaria-
386 naïve volunteers were infected with live, infectious, aseptic, purified, cryopreserved NF54 or 7G8
387 sporozoites (Sanaria® PfSPZ Challenge (NF54) and Sanaria® PfSPZ Challenge (7G8)) manufactured by
388 Sanaria Inc., USA, 7G8 under license from Walter Reed Army Institute of Research. On the day of
389 treatment, up to 50 mL of blood was taken from all volunteers into sodium citrate tubes and processed
390 by Ficoll gradient centrifugation followed by filtration of the washed red blood cell pellet through a
391 Plasmodipur filter (EuroProxima).

392 The MAVACHE trial aimed to sequentially optimize the dose and schedule of PfSPZ Vaccine, verified by
393 randomized, controlled, double-blind immunization and controlled human malaria infection in malaria-
394 naïve, healthy adult volunteers in Germany. The dose optimization phase included a dose-finding phase
395 to evaluate the safety, tolerability and infectivity of 7G8 PfSPZ in malaria-naïve, healthy adult volunteers.
396 A total of nine volunteers received either 800 (n=3), 1,600 (n=3) or 3,200 (n=3) 7G8 PfSPZ. Similar to
397 NF54, 7G8 PfSPZ at a dose of 3,200 PfSPZ resulted in parasitemia in 3/3 of the volunteers, and 2/3
398 volunteers developed parasitemia after infection with 800 and 1,600 PfSPZ, respectively, all
399 administered by direct venous inoculation. Parasite kinetics and clinical presentation are similar to CHMI
400 with NF54 PfSPZ⁵⁸. Samples from five volunteers are included in our study (800 PfSPZ: M08.1D, M08.2D;
401 1,600 PfSPZ: M16.1D; 3,200 PfSPZ: M32.1D, M32.2D) (Table 1, Figure S1). During the regimen
402 verification phase, volunteers were either infected with PfSPZ Vaccine or received placebo, followed by
403 a CHMI three weeks after the last immunization. The placebo group received normal saline instead of
404 PfSPZ Vaccine, but also underwent subsequent CHMI. Samples from three volunteers infected with 7G8
405 PfSPZ (M32.3P, M32.4P, M32.5P) were included in our study (Table 1, Figure S1).

406 The CVac-Tü3 trial assessed the safety and protective efficacy of a simplified Pf sporozoite
407 Chemoprophylaxis Vaccine (PfSPZ-CVac) regimen in healthy malaria-naïve adults in Germany⁴⁴. In total,
408 NF54 PfSPZ of PfSPZ-CVac was administered three times (day 0, 5 and 28) to volunteers receiving parallel
409 chloroquine treatment (1.1×10^5 PfSPZ each), and these volunteers underwent CHMI with 3,200 7G8
410 PfSPZ ten weeks after the last immunization. Samples from three placebo-infected volunteers (C32.1P,
411 C32.2P, C32.3P) could be included into our study (Table 1, Figure S1).

412 In total, samples from eleven malaria-naïve volunteers infected with 7G8 PfSPZ were included in this
413 study.

414

415 **Parasite cell culture**

416 7G8-MRA-152 (contributed by David Walliker), 7G8-MRA-154 (contributed by Dennis E. Kyle) and 7G8-
417 MRA-926 (contributed by Karen Hayton and Tom Wellems) parasites were obtained through BEI
418 Resources, NIAID, NIH. Two frozen vials (termed cell bank aliquots A and B) of 7G8 parasites from
419 Sanaria's working cell bank (lot: SAN03-021214 from 20. February 2014) were separately thawed and
420 cultured in human O+ erythrocytes and in presence of 10% heat-inactivated human serum in parasite
421 culture medium according to standard procedures⁵⁹. To maintain synchronized parasites, 7G8 cultures
422 were treated either with 5% sorbitol⁶⁰. Tight synchronization was performed by percoll-enrichment of
423 schizont⁶¹ followed by sorbitol treatment after 4 hours of cultivation. From cell bank aliquot A ring stage
424 parasites were collected at generations 12, 15 and 24 after thawing, from cell bank aliquot B at
425 generations 6, 13 and 19.

426 Selection of *var2csa* expressing parasites was performed by panning on plastic dishes coated with 50
427 $\mu\text{g/ml}$ bovine trachea CSA (Sigma), as described previously⁶². Subclones of Pf7G8 cell bank aliquot A
428 were generated by limiting dilution cloning, as described previously⁶³.

429

430 **Western blot analysis**

431 Trophozoite stage cultures were treated with 0.075% saponin in PBS to release hemoglobin from the
432 erythrocytes. Parasites and membrane ghosts were pelleted by centrifugation, washed three times in

433 PBS containing protease inhibitors (cComplete EDTA free, Roche), and extracted in 2 x Laemmli buffer.
434 The protein extracts were separated on 3–8% Tris-Acetate gels (Invitrogen) and transferred to
435 nitrocellulose membranes (Millipore). The blots were probed with monoclonal mouse anti-ATS (6HI)
436 antibody⁶⁴ or rabbit anti-*Plasmodium* aldolase antibody (abcam, ab207494) as loading control.

437

438 **gDNA purification for whole genome sequencing**

439 For gDNA sequencing, 150 mL Pf cell culture with >10% parasitemia were harvested for the 7G8 cell
440 bank aliquot A subclones A1G9, A2E10, and A2G2 and gDNA isolation was performed using the
441 MasterPure™ Complete DNA purification kit (Lucigen) according to the manufacturer’s instructions “Cell
442 samples” followed by “Complete Removal of RNA” with additional RNase I treatment. The gDNA samples
443 were checked for degradation and RNA contamination on an agarose gel and quantified with the Qubit™
444 dsDNA BR Assay Kit (ThermoFischer).

445

446 **RNA purification and cDNA synthesis**

447 Red blood cells were settled by centrifugation and completely lysed in 5 volumes of pre-warmed TRIzol
448 (ThermoFisher). Samples were stored at -80°C until RNA purification. The RNeasy Mini kit with on-
449 column DNase I treatment (Qiagen) was used for RNA purification. The absence of gDNA was checked
450 for each sample using 50 ng RNA and the *skeleton-binding protein 1 (sbp1)* primer set (Table S1). cDNA
451 synthesis was performed as previously described³³.

452

453 **Quantitative real-time PCR**

454 The LightCycler 480 (Roche) was used for quantitative real-time PCR analysis using the provided
455 LightCycler®480 software release 1.5.1.62 SP3 as previously described³³. Briefly, cDNA template was
456 mixed with QuantiTect SYBR Green PCR reagent (Qiagen) and 0.3 μM sense and antisense primer in a
457 final volume of 10 μl. Reactions were incubated at 95°C for 15 min, then subjected to 40 cycles of 95°C
458 for 15 s and 60°C for 1 min followed by a melting step (60–95°C). The specificity of each primer pair was
459 confirmed by dissociation curve analysis after each qPCR run. Ct calculation was done using the fit points

460 analysis method provided by the software. Expression of *arginyl-tRNA synthetase* (PF3D7_1218600) was
461 used for normalization and Ct values obtained by analysis of 2.5 ng gDNA from Sanaria's working cell
462 bank parasites were used for calibration. Relative quantification of the 7G8 *var* repertoire by $2^{-\Delta\Delta Ct}$
463 analysis was performed using newly designed primer sets for 7G8 (Table S1). Furthermore, primer pairs
464 targeting the housekeeping gene *fructose-bisphosphate aldolase* as well as the ring stage control *sbp1*
465 were included (Table S1). Relative expression data (RELEXP) were corrected for amplification efficiency
466 of each newly designed primer pair, which was determined by dilution of a single gDNA from 7G8 over
467 5–6 logs of concentration (Table S1). For further characterization, the full 7G8 primer set was checked
468 for cross-reactivity with NF54 gDNA³³, but only primers targeting the partial gene Pf7G8_120024200
469 produced a specific amplicon with NF54 gDNA.

470

471 RNA and gDNA sequencing

472 RNA from cell bank parasites (aliquot B, generation 13 after thawing) was purified and processed as
473 previously described⁶⁵. Briefly, absence of genomic DNA was checked, human globin mRNA was
474 depleted, and RNA quantity and quality were assessed with an Bioanalyzer (RIN value 8.4). A 100–500
475 bp library was prepared using the NEBNext Ultra Directional RNA Library Prep Kit for Illumina including
476 the amplification with the KAPA polymerase, and RNA sequencing on an Illumina HiSeq4000 was
477 conducted by BGI Genomics Co., Hongkong. Approximately 12.6 million clean reads were obtained for
478 pre-mosquito cell bank parasites, resulting in 6.3 million paired-end 100 bp reads.

479 Library construction of gDNA and paired-end 150 bp sequencing of approximately 350 bp fragments
480 (range: 230–430 bp) on the DNBseq platform was done by BGI Genomics Co., Hongkong with coverage
481 of approximately 130x (range: 129x–136x).

482

483 RNA-seq data analysis

484 After successful quality control of RNA-seq reads with FastQC v0.11.8
485 (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>)⁶⁶, the reads were aligned to the Pf 7G8
486 genome available from the PlasmoDB genome database release 45 or to the Pf 7G8 exon 1 *var* gene

487 sequences (Data S1)³⁷ using the RNA-seq aligner STAR v2.7.3a⁶⁷ allowing for a maximum mismatch of
488 1 (--outFilterMismatchNmax 1). Prior to read alignment, STAR was used to generate an index using the
489 genome sequence fasta file (PlasmoDB-45_Pfalciparum7G8_Genome.fasta) or the exon 1 *var* gene
490 sequences from Data S1. The mapped reads in Sequence Alignment/Map (SAM) format were then
491 summarized using the featureCounts⁶⁸ function of the Rsubread R package⁶⁹, filtering for a minimum
492 fragment length of 85 bp for paired-end reads (minFragLength=85), as was done previously⁶⁵. While
493 the annotation file PlasmoDB-45_Pfalciparum7G8.gff was used to summarize read counts across the
494 entire Pf 7G8 genome, a simplified annotation format (SAF) file was built from *var* gene index files and
495 supplied as annotation file to featureCounts.

496 The R package edgeR⁷⁰ was used to compute FPKM gene expression values using its rpkm function. The
497 gene lengths of transcripts required for FPKM normalization were extracted from the PlasmoDB-
498 45_Pfalciparum7G8_AnnotatedTranscripts.fasta file or the coding_nt.fa file (for the specific *var* gene
499 assembly mapping) by indexing it using SAMtools⁷¹ faidx and extracting the first two columns containing
500 sequence name and length.

501 Raw and normalized RNA-seq data were submitted to the BioStudies ArrayExpress collection (E-MTAB-
502 12157).

503

504 **gDNA-seq data analysis, mapping and variant calling**

505 The raw reads were trimmed, mapped and variant calls were made using the CLC Genomics Workbench
506 version 21 for Linux. Since all subclonal lines were cloned just before sequencing by limiting dilution,
507 only variant calls with >90% reads mapped to the alternative allele were considered. Manual inspection
508 further reduced the number of reliable variants, as the AT-rich genome of Pf is prone to sequencing
509 errors within repetitive regions. Results and raw data from gDNA-seq were submitted to the BioStudies
510 ArrayExpress collection (E-MTAB-12158).

511

512 **Chromatin immunoprecipitation analysis (ChIP-qPCR)**

513 Chromatin immunoprecipitation was performed essentially as described previously ⁷². Briefly, 1%
514 paraformaldehyde-crosslinked chromatin was sheared by sonication and the soluble fraction was used
515 for immunoprecipitation overnight using protein G coupled sepharose beads (GE Healthcare).
516 Antibodies used for CHIP were rabbit anti-H3 (Abcam ab1791), anti-H3K9me3 (Active Motif 39161), anti-
517 H3K27ac (Abcam ab4729), and anti-H2A.Z ²⁴. Washed immune complexes were eluted and de-
518 crosslinked over night at 45°C in the presence of 500 mM NaCl. After proteinase K treatment for 1h at
519 37°C, the DNA was purified from each CHIP and input sample using the MinElute kit (Qiagen 28006) and
520 analyzed by qPCR on an Applied Biosystems 7900HT fast real-time PCR system using SYBR Green PCR
521 MasterMix (ThermoFisher Scientific 4309155) and 0.9 μM sense and antisense primers (Table S1) in a
522 final volume of 10 μl. CHIP enrichment at each genomic locus was calculated as % of input DNA, and
523 histone modifications and H2A.Z were normalized relative to H3.

524

525 **Data analysis and statistics**

526 Categorical variables were displayed as frequencies and percentages, and continuous variables as
527 median and interquartile range (IQR).

528 The differences between the two molecular methods qPCR and RNA-seq were analyzed using a Bland-
529 Altman plot showing the agreement between two quantitative measurements. The differences between
530 log-transformed measurements were plotted on the y-axis and the mean of the respective qPCR and
531 RNA-seq results on the x-axis. Thus, the graph shows the deviation of the analysis results with respect
532 to the expression level.

533 The expressions of *var* genes per patient were summarized in a heat map accompanied by a dendrogram
534 of hierarchical cluster analysis applied to the expression pattern of patients. To correct for individual
535 differences in the overall *var* transcript levels, the level for each *var* gene was normalized against total
536 *var* transcript level in each sample. *Var* gene expressions within patient groups were summarized using
537 the median and interquartile range (IQR). Boxplots showing the minimum, maximum, IQR, and median
538 were used to graphically represent group expressions. Outliers, defined as values above or below the
539 median +/- 1.5 times the IQR, are plotted outside the whiskers of the boxplot. Correlations between

540 individual *var* gene expressions are calculated using the Pearson correlation coefficient (PCC) with the
541 log-transformed measurements.

542

543 **Funding**

544 JH, ME, PGK, BM and AB received funding for the clinical trial and the *var* gene expression analysis by
545 the Federal Ministry of Education and Research in the framework of the German Centre for Infection
546 Research (DZIF) (TTU 03.702 Clinical Trial Platform and TTU 03.703 Clinical Research Group)
547 (<http://www.dzif.de/>). This work was supported by the DFG Research Infrastructure NGS_CC (project
548 #1016) as part of the Next Generation Sequencing Competence Network (project 423957469). NGS
549 analyses were carried out at the production site WGGC-Bonn. AB and MP received the DFG grants BA
550 5213/6-1 and PE 1618/4-1 (project #433302244), respectively, as part of the DFG Sequencing call 2019.
551 JSWM, YDH and AB were funded by the German Research Foundation (DFG) grants BA 5213/3-1 (project
552 #323759012) and BA 5213/6-1 (project #433302244). Manufacture of Sanaria® PfSPZ Vaccine, PfSPZ
553 Challenge (NF54) and PfSPZ Challenge (7G8) was funded in part by the National Institute of Allergy and
554 Infectious Diseases of the National Institutes of Health under SBIR award numbers 5R44AI058375
555 and 5R44AI055229. JCS, KAM and AD were funded by awards U19 AI110820 and R01 AI141900, from
556 the National Institute for Allergy and Infectious Diseases, National Institutes of Health. The funders had
557 no role in study design, data collection and analysis, decision to publish, or preparation of the
558 manuscript.

559

560 **Acknowledgements**

561 We thank all volunteers who participated in the trials at the Institute of Tropical Medicine in Tübingen,
562 Germany, and the entire study team. We thank Sanaria Inc. for providing the 7G8 working cell bank
563 parasites and the PfSPZ Challenge (7G8) used in the CHMI trials and Balázs Horváth for his help with
564 data analysis, mapping and variant calling. The following reagents were obtained through BEI Resources,
565 NIAID, NIH: *Plasmodium falciparum*, Strain 7G8, MRA-152, contributed by David Walliker, MRA-154,
566 contributed by Dennis E. Kyle and MRA-926, contributed by Karen Hayton and Tom Wellems.

567

568 **References**

- 569 1. Miller, L.H., Baruch, D.I., Marsh, K., and Doumbo, O.K. (2002). The pathogenic basis of malaria.
570 Nature 415, 673-679. [10.1038/415673a](https://doi.org/10.1038/415673a).
- 571 2. Gardner, M.J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R.W., Carlton, J.M., Pain, A.,
572 Nelson, K.E., Bowman, S., et al. (2002). Genome sequence of the human malaria parasite
573 Plasmodium falciparum. Nature 419, 498-511. [10.1038/nature01097](https://doi.org/10.1038/nature01097).
- 574 3. Kraemer, S.M., and Smith, J.D. (2003). Evidence for the importance of genetic structuring to the
575 structural and functional specialization of the Plasmodium falciparum var gene family. Mol
576 Microbiol 50, 1527-1538. [10.1046/j.1365-2958.2003.03814.x](https://doi.org/10.1046/j.1365-2958.2003.03814.x).
- 577 4. Lavstsen, T., Salanti, A., Jensen, A.T., Arnot, D.E., and Theander, T.G. (2003). Sub-grouping of
578 Plasmodium falciparum 3D7 var genes based on sequence analysis of coding and non-coding
579 regions. Malar J 2, 27. [10.1186/1475-2875-2-27](https://doi.org/10.1186/1475-2875-2-27).
- 580 5. Rask, T.S., Hansen, D.A., Theander, T.G., Gorm Pedersen, A., and Lavstsen, T. (2010).
581 Plasmodium falciparum erythrocyte membrane protein 1 diversity in seven genomes--divide
582 and conquer. PLoS Comput Biol 6. [10.1371/journal.pcbi.1000933](https://doi.org/10.1371/journal.pcbi.1000933).
- 583 6. Jensen, A.T., Magistrado, P., Sharp, S., Joergensen, L., Lavstsen, T., Chiuicchiuini, A., Salanti, A.,
584 Vestergaard, L.S., Lusingu, J.P., Hermsen, R., et al. (2004). Plasmodium falciparum associated
585 with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes.
586 J Exp Med 199, 1179-1190. [10.1084/jem.20040274](https://doi.org/10.1084/jem.20040274).
- 587 7. Bull, P.C., Berriman, M., Kyes, S., Quail, M.A., Hall, N., Kortok, M.M., Marsh, K., and Newbold,
588 C.I. (2005). Plasmodium falciparum variant surface antigen expression patterns during malaria.
589 PLoS Pathog 1, e26. [10.1371/journal.ppat.0010026](https://doi.org/10.1371/journal.ppat.0010026).
- 590 8. Warimwe, G.M., Keane, T.M., Fegan, G., Musyoki, J.N., Newton, C.R., Pain, A., Berriman, M.,
591 Marsh, K., and Bull, P.C. (2009). Plasmodium falciparum var gene expression is modified by host
592 immunity. Proc Natl Acad Sci U S A 106, 21801-21806. [10.1073/pnas.0907590106](https://doi.org/10.1073/pnas.0907590106).

- 593 9. Lavstsen, T., Turner, L., Saguti, F., Magistrado, P., Rask, T.S., Jespersen, J.S., Wang, C.W., Berger,
594 S.S., Baraka, V., Marquard, A.M., et al. (2012). Plasmodium falciparum erythrocyte membrane
595 protein 1 domain cassettes 8 and 13 are associated with severe malaria in children. Proc Natl
596 Acad Sci U S A 109, E1791-1800. 10.1073/pnas.1120455109.
- 597 10. Jespersen, J.S., Wang, C.W., Mkumbaye, S.I., Minja, D.T., Petersen, B., Turner, L., Petersen, J.E.,
598 Lusingu, J.P., Theander, T.G., and Lavstsen, T. (2016). Plasmodium falciparum var genes
599 expressed in children with severe malaria encode CIDRalpha1 domains. EMBO Mol Med 8, 839-
600 850. 10.15252/emmm.201606188.
- 601 11. Kessler, A., Dankwa, S., Bernabeu, M., Harawa, V., Danziger, S.A., Duffy, F., Kampondeni, S.D.,
602 Potchen, M.J., Dambrauskas, N., Vigdorovich, V., et al. (2017). Linking EPCR-Binding PfEMP1 to
603 Brain Swelling in Pediatric Cerebral Malaria. Cell Host Microbe 22, 601-614 e605.
604 10.1016/j.chom.2017.09.009.
- 605 12. Kaestli, M., Cockburn, I.A., Cortes, A., Baea, K., Rowe, J.A., and Beck, H.P. (2006). Virulence of
606 malaria is associated with differential expression of Plasmodium falciparum var gene subgroups
607 in a case-control study. J Infect Dis 193, 1567-1574. 10.1086/503776.
- 608 13. Salanti, A., Dahlback, M., Turner, L., Nielsen, M.A., Barfod, L., Magistrado, P., Jensen, A.T.,
609 Lavstsen, T., Ofori, M.F., Marsh, K., et al. (2004). Evidence for the involvement of VAR2CSA in
610 pregnancy-associated malaria. J Exp Med 200, 1197-1203. 10.1084/jem.20041579.
- 611 14. Otto, T.D., Bohme, U., Sanders, M., Reid, A., Bruske, E.I., Duffy, C.W., Bull, P.C., Pearson, R.D.,
612 Abdi, A., Dimonte, S., et al. (2018). Long read assemblies of geographically dispersed
613 Plasmodium falciparum isolates reveal highly structured subtelomeres. Wellcome Open Res 3,
614 52. 10.12688/wellcomeopenres.14571.1.
- 615 15. Wahlgren, M., Goel, S., and Akhouri, R.R. (2017). Variant surface antigens of Plasmodium
616 falciparum and their roles in severe malaria. Nat Rev Microbiol 15, 479-491.
617 10.1038/nrmicro.2017.47.
- 618 16. Deitsch, K.W., Calderwood, M.S., and Wellems, T.E. (2001). Malaria. Cooperative silencing
619 elements in var genes. Nature 412, 875-876. 10.1038/35091146.

- 620 17. Calderwood, M.S., Gannoun-Zaki, L., Wellems, T.E., and Deitsch, K.W. (2003). Plasmodium
621 falciparum var genes are regulated by two regions with separate promoters, one upstream of
622 the coding region and a second within the intron. *J Biol Chem* 278, 34125-34132.
623 10.1074/jbc.M213065200.
- 624 18. Voss, T.S., Kaestli, M., Vogel, D., Bopp, S., and Beck, H.P. (2003). Identification of nuclear
625 proteins that interact differentially with Plasmodium falciparum var gene promoters. *Mol*
626 *Microbiol* 48, 1593-1607. 10.1046/j.1365-2958.2003.03528.x.
- 627 19. Fraschka, S.A., Henderson, R.W., and Bartfai, R. (2016). H3.3 demarcates GC-rich coding and
628 subtelomeric regions and serves as potential memory mark for virulence gene expression in
629 Plasmodium falciparum. *Sci Rep* 6, 31965. 10.1038/srep31965.
- 630 20. Duraisingh, M.T., Voss, T.S., Marty, A.J., Duffy, M.F., Good, R.T., Thompson, J.K., Freitas-Junior,
631 L.H., Scherf, A., Crabb, B.S., and Cowman, A.F. (2005). Heterochromatin silencing and locus
632 repositioning linked to regulation of virulence genes in Plasmodium falciparum. *Cell* 121, 13-24.
633 10.1016/j.cell.2005.01.036.
- 634 21. Ralph, S.A., Scheidig-Benatar, C., and Scherf, A. (2005). Antigenic variation in Plasmodium
635 falciparum is associated with movement of var loci between subnuclear locations. *Proc Natl*
636 *Acad Sci U S A* 102, 5414-5419. 10.1073/pnas.0408883102.
- 637 22. Lopez-Rubio, J.J., Gontijo, A.M., Nunes, M.C., Issar, N., Hernandez Rivas, R., and Scherf, A.
638 (2007). 5' flanking region of var genes nucleate histone modification patterns linked to
639 phenotypic inheritance of virulence traits in malaria parasites. *Mol Microbiol* 66, 1296-1305.
640 10.1111/j.1365-2958.2007.06009.x.
- 641 23. Volz, J.C., Bartfai, R., Petter, M., Langer, C., Josling, G.A., Tsuboi, T., Schwach, F., Baum, J.,
642 Rayner, J.C., Stunnenberg, H.G., et al. (2012). PfSET10, a Plasmodium falciparum
643 methyltransferase, maintains the active var gene in a poised state during parasite division. *Cell*
644 *Host Microbe* 11, 7-18. 10.1016/j.chom.2011.11.011.

- 645 24. Petter, M., Lee, C.C., Byrne, T.J., Boysen, K.E., Volz, J., Ralph, S.A., Cowman, A.F., Brown, G.V.,
646 and Duffy, M.F. (2011). Expression of *P. falciparum* var genes involves exchange of the histone
647 variant H2A.Z at the promoter. *PLoS Pathog* 7, e1001292. [10.1371/journal.ppat.1001292](https://doi.org/10.1371/journal.ppat.1001292).
- 648 25. Petter, M., Selvarajah, S.A., Lee, C.C., Chin, W.H., Gupta, A.P., Bozdech, Z., Brown, G.V., and
649 Duffy, M.F. (2013). H2A.Z and H2B.Z double-variant nucleosomes define intergenic regions and
650 dynamically occupy var gene promoters in the malaria parasite *Plasmodium falciparum*. *Mol*
651 *Microbiol* 87, 1167-1182. [10.1111/mmi.12154](https://doi.org/10.1111/mmi.12154).
- 652 26. Jiang, L., Mu, J., Zhang, Q., Ni, T., Srinivasan, P., Rayavara, K., Yang, W., Turner, L., Lavstsen, T.,
653 Theander, T.G., et al. (2013). PfSETvs methylation of histone H3K36 represses virulence genes
654 in *Plasmodium falciparum*. *Nature* 499, 223-227. [10.1038/nature12361](https://doi.org/10.1038/nature12361).
- 655 27. Flueck, C., Bartfai, R., Volz, J., Niederwieser, I., Salcedo-Amaya, A.M., Alako, B.T., Ehlgren, F.,
656 Ralph, S.A., Cowman, A.F., Bozdech, Z., et al. (2009). *Plasmodium falciparum* heterochromatin
657 protein 1 marks genomic loci linked to phenotypic variation of exported virulence factors. *PLoS*
658 *Pathog* 5, e1000569. [10.1371/journal.ppat.1000569](https://doi.org/10.1371/journal.ppat.1000569).
- 659 28. Perez-Toledo, K., Rojas-Meza, A.P., Mancio-Silva, L., Hernandez-Cuevas, N.A., Delgadillo, D.M.,
660 Vargas, M., Martinez-Calvillo, S., Scherf, A., and Hernandez-Rivas, R. (2009). *Plasmodium*
661 *falciparum* heterochromatin protein 1 binds to tri-methylated histone 3 lysine 9 and is linked to
662 mutually exclusive expression of var genes. *Nucleic Acids Res* 37, 2596-2606.
663 [10.1093/nar/gkp115](https://doi.org/10.1093/nar/gkp115).
- 664 29. Lopez-Rubio, J.J., Mancio-Silva, L., and Scherf, A. (2009). Genome-wide analysis of
665 heterochromatin associates clonally variant gene regulation with perinuclear repressive centers
666 in malaria parasites. *Cell Host Microbe* 5, 179-190. [10.1016/j.chom.2008.12.012](https://doi.org/10.1016/j.chom.2008.12.012).
- 667 30. Tang, J., Chisholm, S.A., Yeoh, L.M., Gilson, P.R., Papenfuss, A.T., Day, K.P., Petter, M., and Duffy,
668 M.F. (2020). Histone modifications associated with gene expression and genome accessibility
669 are dynamically enriched at *Plasmodium falciparum* regulatory sequences. *Epigenetics*
670 *Chromatin* 13, 50. [10.1186/s13072-020-00365-5](https://doi.org/10.1186/s13072-020-00365-5).

- 671 31. Recker, M., Buckee, C.O., Serazin, A., Kyes, S., Pinches, R., Christodoulou, Z., Springer, A.L.,
672 Gupta, S., and Newbold, C.I. (2011). Antigenic variation in *Plasmodium falciparum* malaria
673 involves a highly structured switching pattern. *PLoS Pathog* 7, e1001306.
674 10.1371/journal.ppat.1001306.
- 675 32. Ukaegbu, U.E., Zhang, X., Heinberg, A.R., Wele, M., Chen, Q., and Deitsch, K.W. (2015). A Unique
676 Virulence Gene Occupies a Principal Position in Immune Evasion by the Malaria Parasite
677 *Plasmodium falciparum*. *PLoS Genet* 11, e1005234. 10.1371/journal.pgen.1005234.
- 678 33. Bachmann, A., Bruske, E., Krumkamp, R., Turner, L., Wichers, J.S., Petter, M., Held, J., Duffy,
679 M.F., Sim, B.K.L., Hoffman, S.L., et al. (2019). Controlled human malaria infection with
680 *Plasmodium falciparum* demonstrates impact of naturally acquired immunity on virulence gene
681 expression. *PLoS Pathog* 15, e1007906. 10.1371/journal.ppat.1007906.
- 682 34. Wang, C.W., Hermsen, C.C., Sauerwein, R.W., Arnot, D.E., Theander, T.G., and Lavstsen, T.
683 (2009). The *Plasmodium falciparum* var gene transcription strategy at the onset of blood stage
684 infection in a human volunteer. *Parasitol Int* 58, 478-480. 10.1016/j.parint.2009.07.004.
- 685 35. Bachmann, A., Petter, M., Krumkamp, R., Esen, M., Held, J., Scholz, J.A., Li, T., Sim, B.K., Hoffman,
686 S.L., Kremsner, P.G., et al. (2016). Mosquito Passage Dramatically Changes var Gene Expression
687 in Controlled Human *Plasmodium falciparum* Infections. *PLoS Pathog* 12, e1005538.
688 10.1371/journal.ppat.1005538.
- 689 36. Spence, P.J., Jarra, W., Levy, P., Reid, A.J., Chappell, L., Brugat, T., Sanders, M., Berriman, M.,
690 and Langhorne, J. (2013). Vector transmission regulates immune control of *Plasmodium*
691 virulence. *Nature* 498, 228-231. 10.1038/nature12231.
- 692 37. Moser, K.A., Drabek, E.F., Dwivedi, A., Stucke, E.M., Crabtree, J., Dara, A., Shah, Z., Adams, M.,
693 Li, T., Rodrigues, P.T., et al. (2020). Strains used in whole organism *Plasmodium falciparum*
694 vaccine trials differ in genome structure, sequence, and immunogenic potential. *Genome Med*
695 12, 6. 10.1186/s13073-019-0708-9.
- 696 38. Silva, J.C., Dwivedi, A., Moser, K.A., Sissoko, M.S., Epstein, J.E., Healy, S.A., Lyke, K.E.,
697 Mordmuller, B., Kremsner, P.G., Duffy, P.E., et al. (2022). *Plasmodium falciparum* 7G8 challenge

- 698 provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa. Nat
699 Commun 13, 3390. 10.1038/s41467-022-30882-8.
- 700 39. Preston, M.D., Campino, S., Assefa, S.A., Echeverry, D.F., Ocholla, H., Amambua-Ngwa, A.,
701 Stewart, L.B., Conway, D.J., Borrmann, S., Michon, P., et al. (2014). A barcode of organellar
702 genome polymorphisms identifies the geographic origin of Plasmodium falciparum strains. Nat
703 Commun 5, 4052. 10.1038/ncomms5052.
- 704 40. Burkot, T.R., Williams, J.L., and Schneider, I. (1984). Infectivity to mosquitoes of Plasmodium
705 falciparum clones grown in vitro from the same isolate. Trans R Soc Trop Med Hyg 78, 339-341.
706 10.1016/0035-9203(84)90114-7.
- 707 41. Aurrecochea, C., Brestelli, J., Brunk, B.P., Dommer, J., Fischer, S., Gajria, B., Gao, X., Gingle, A.,
708 Grant, G., Harb, O.S., et al. (2009). PlasmoDB: a functional genomic database for malaria
709 parasites. Nucleic Acids Res 37, D539-543. 10.1093/nar/gkn814.
- 710 42. Otto, T.D., Assefa, S.A., Bohme, U., Sanders, M.J., Kwiatkowski, D., Pf3k, c., Berriman, M., and
711 Newbold, C. (2019). Evolutionary analysis of the most polymorphic gene family in falciparum
712 malaria. Wellcome Open Res 4, 193. 10.12688/wellcomeopenres.15590.1.
- 713 43. Mordmuller, B., Sulyok, Z., Sulyok, M., Molnar, Z., Lalremruata, A., Calle, C.L., Bayon, P.G., Esen,
714 M., Gmeiner, M., Held, J., et al. (2022). A PfSPZ vaccine immunization regimen equally
715 protective against homologous and heterologous controlled human malaria infection. NPJ
716 Vaccines 7, 100. 10.1038/s41541-022-00510-z.
- 717 44. Sulyok, Z., Fendel, R., Eder, B., Lorenz, F.R., Kc, N., Karnahl, M., Lalremruata, A., Nguyen, T.T.,
718 Held, J., Adjadi, F.A.C., et al. (2021). Heterologous protection against malaria by a simple
719 chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat Commun 12, 2518.
720 10.1038/s41467-021-22740-w.
- 721 45. Barcons-Simon, A., Cordon-Obras, C., Guizetti, J., Bryant, J.M., and Scherf, A. (2020). CRISPR
722 Interference of a Clonally Variant GC-Rich Noncoding RNA Family Leads to General Repression
723 of var Genes in Plasmodium falciparum. mBio 11. 10.1128/mBio.03054-19.

- 724 46. Salanti, A., Staalsoe, T., Lavstsen, T., Jensen, A.T., Sowa, M.P., Arnot, D.E., Hviid, L., and
725 Theander, T.G. (2003). Selective upregulation of a single distinctly structured var gene in
726 chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated
727 malaria. *Mol Microbiol* 49, 179-191. [10.1046/j.1365-2958.2003.03570.x](https://doi.org/10.1046/j.1365-2958.2003.03570.x).
- 728 47. Dorin-Semblat, D., Tetard, M., Claes, A., Semblat, J.P., Dechavanne, S., Fourati, Z., Hamelin, R.,
729 Armand, F., Matesic, G., Nunes-Silva, S., et al. (2019). Phosphorylation of the VAR2CSA
730 extracellular region is associated with enhanced adhesive properties to the placental receptor
731 CSA. *PLoS Biol* 17, e3000308. [10.1371/journal.pbio.3000308](https://doi.org/10.1371/journal.pbio.3000308).
- 732 48. Gangnard, S., Chene, A., Dechavanne, S., Srivastava, A., Avril, M., Smith, J.D., and Gamain, B.
733 (2019). VAR2CSA binding phenotype has ancient origin and arose before Plasmodium
734 falciparum crossed to humans: implications in placental malaria vaccine design. *Sci Rep* 9,
735 16978. [10.1038/s41598-019-53334-8](https://doi.org/10.1038/s41598-019-53334-8).
- 736 49. Rovira-Graells, N., Gupta, A.P., Planet, E., Crowley, V.M., Mok, S., Ribas de Pouplana, L., Preiser,
737 P.R., Bozdech, Z., and Cortes, A. (2012). Transcriptional variation in the malaria parasite
738 Plasmodium falciparum. *Genome Res* 22, 925-938. [10.1101/gr.129692.111](https://doi.org/10.1101/gr.129692.111).
- 739 50. Milne, K., Ivens, A., Reid, A.J., Lotkowska, M.E., O'Toole, A., Sankaranarayanan, G., Munoz
740 Sandoval, D., Nahrendorf, W., Regnault, C., Edwards, N.J., et al. (2021). Mapping immune
741 variation and var gene switching in naive hosts infected with Plasmodium falciparum. *Elife* 10,
742 10.7554/eLife.62800.
- 743 51. Pickford, A.K., Michel-Todo, L., Dupuy, F., Mayor, A., Alonso, P.L., Lavazec, C., and Cortes, A.
744 (2021). Expression Patterns of Plasmodium falciparum Clonally Variant Genes at the Onset of a
745 Blood Infection in Malaria-Naive Humans. *mBio* 12, e0163621. [10.1128/mBio.01636-21](https://doi.org/10.1128/mBio.01636-21).
- 746 52. Zanghi, G., Vembar, S.S., Baumgarten, S., Ding, S., Guizetti, J., Bryant, J.M., Mattei, D., Jensen,
747 A.T.R., Renia, L., Goh, Y.S., et al. (2018). A Specific PfEMP1 Is Expressed in P. falciparum
748 Sporozoites and Plays a Role in Hepatocyte Infection. *Cell Rep* 22, 2951-2963.
749 [10.1016/j.celrep.2018.02.075](https://doi.org/10.1016/j.celrep.2018.02.075).

- 750 53. Gomez-Diaz, E., Yerbanga, R.S., Lefevre, T., Cohuet, A., Rowley, M.J., Ouedraogo, J.B., and
751 Corces, V.G. (2017). Epigenetic regulation of *Plasmodium falciparum* clonally variant gene
752 expression during development in *Anopheles gambiae*. *Sci Rep* 7, 40655. [10.1038/srep40655](https://doi.org/10.1038/srep40655).
- 753 54. Duffy, M.F., Selvarajah, S.A., Josling, G.A., and Petter, M. (2014). Epigenetic regulation of the
754 *Plasmodium falciparum* genome. *Brief Funct Genomics* 13, 203-216. [10.1093/bfgp/elt047](https://doi.org/10.1093/bfgp/elt047).
- 755 55. Duffy, M.F., Tang, J., Sumardy, F., Nguyen, H.H., Selvarajah, S.A., Josling, G.A., Day, K.P., Petter,
756 M., and Brown, G.V. (2017). Activation and clustering of a *Plasmodium falciparum* var gene are
757 affected by subtelomeric sequences. *FEBS J* 284, 237-257. [10.1111/febs.13967](https://doi.org/10.1111/febs.13967).
- 758 56. Frank, M., Dzikowski, R., Amulic, B., and Deitsch, K. (2007). Variable switching rates of malaria
759 virulence genes are associated with chromosomal position. *Mol Microbiol* 64, 1486-1498.
760 [10.1111/j.1365-2958.2007.05736.x](https://doi.org/10.1111/j.1365-2958.2007.05736.x).
- 761 57. Duffy, M.F., Byrne, T.J., Elliott, S.R., Wilson, D.W., Rogerson, S.J., Beeson, J.G., Noviyanti, R., and
762 Brown, G.V. (2005). Broad analysis reveals a consistent pattern of var gene transcription in
763 *Plasmodium falciparum* repeatedly selected for a defined adhesion phenotype. *Mol Microbiol*
764 56, 774-788. [10.1111/j.1365-2958.2005.04577.x](https://doi.org/10.1111/j.1365-2958.2005.04577.x).
- 765 58. Mordmuller, B., Supan, C., Sim, K.L., Gomez-Perez, G.P., Ospina Salazar, C.L., Held, J., Bolte, S.,
766 Esen, M., Tschan, S., Joanny, F., et al. (2015). Direct venous inoculation of *Plasmodium*
767 *falciparum* sporozoites for controlled human malaria infection: a dose-finding trial in two
768 centres. *Malar J* 14, 117. [10.1186/s12936-015-0628-0](https://doi.org/10.1186/s12936-015-0628-0).
- 769 59. Trager, W., and Jensen, J.B. (1997). Continuous culture of *Plasmodium falciparum*: its impact on
770 malaria research. *Int J Parasitol* 27, 989-1006. [10.1016/s0020-7519\(97\)00080-5](https://doi.org/10.1016/s0020-7519(97)00080-5).
- 771 60. Lambros, C., and Vanderberg, J.P. (1979). Synchronization of *Plasmodium falciparum*
772 erythrocytic stages in culture. *J Parasitol* 65, 418-420.
- 773 61. Rivadeneira, E.M., Wasserman, M., and Espinal, C.T. (1983). Separation and concentration of
774 schizonts of *Plasmodium falciparum* by Percoll gradients. *J Protozool* 30, 367-370.
775 [10.1111/j.1550-7408.1983.tb02932.x](https://doi.org/10.1111/j.1550-7408.1983.tb02932.x).

- 776 62. Noviyanti, R., Brown, G.V., Wickham, M.E., Duffy, M.F., Cowman, A.F., and Reeder, J.C. (2001).
777 Multiple var gene transcripts are expressed in Plasmodium falciparum infected erythrocytes
778 selected for adhesion. *Mol Biochem Parasitol* 114, 227-237. 10.1016/s0166-6851(01)00266-3.
- 779 63. Thomas, J.A., Collins, C.R., Das, S., Hackett, F., Graindorge, A., Bell, D., Deu, E., and Blackman,
780 M.J. (2016). Development and Application of a Simple Plaque Assay for the Human Malaria
781 Parasite Plasmodium falciparum. *PLoS One* 11, e0157873. 10.1371/journal.pone.0157873.
- 782 64. Crabb, B.S., Cooke, B.M., Reeder, J.C., Waller, R.F., Caruana, S.R., Davern, K.M., Wickham, M.E.,
783 Brown, G.V., Coppel, R.L., and Cowman, A.F. (1997). Targeted gene disruption shows that knobs
784 enable malaria-infected red cells to cytoadhere under physiological shear stress. *Cell* 89, 287-
785 296. 10.1016/s0092-8674(00)80207-x.
- 786 65. Wichers, J.S., Scholz, J.A.M., Strauss, J., Witt, S., Lill, A., Ehnold, L.I., Neupert, N., Liffner, B.,
787 Luhken, R., Petter, M., et al. (2019). Dissecting the Gene Expression, Localization, Membrane
788 Topology, and Function of the Plasmodium falciparum STEVOR Protein Family. *mBio* 10.
789 10.1128/mBio.01500-19.
- 790 66. Andrews, S. (2010). FastQC: A quality control tool for high throughput sequence data.
- 791 67. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and
792 Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15-21.
793 10.1093/bioinformatics/bts635.
- 794 68. Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose program
795 for assigning sequence reads to genomic features. *Bioinformatics* 30, 923-930.
796 10.1093/bioinformatics/btt656.
- 797 69. Liao, Y., Smyth, G.K., and Shi, W. (2013). The Subread aligner: fast, accurate and scalable read
798 mapping by seed-and-vote. *Nucleic Acids Res* 41, e108. 10.1093/nar/gkt214.
- 799 70. Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for
800 differential expression analysis of digital gene expression data. *Bioinformatics* 26, 139-140.
801 10.1093/bioinformatics/btp616.

- 802 71. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G.,
803 Durbin, R., and Genome Project Data Processing, S. (2009). The Sequence Alignment/Map
804 format and SAMtools. *Bioinformatics* 25, 2078-2079. 10.1093/bioinformatics/btp352.
- 805 72. Quinn, J.E., Jeninga, M.D., Limm, K., Pareek, K., Meissgeier, T., Bachmann, A., Duffy, M.F., and
806 Petter, M. (2022). The Putative Bromodomain Protein PfBDP7 of the Human Malaria Parasite
807 *Plasmodium Falciparum* Cooperates With PfBDP1 in the Silencing of Variant Surface Antigen
808 Expression. *Front Cell Dev Biol* 10, 816558. 10.3389/fcell.2022.816558.

809

810 Figures

811

812 **Table 1: Overview of volunteer characteristics infected with PfSPZ. Parasite counts were determined on**
813 **the day of treatment/sampling by either thick blood smear (TBS) or qPCR.**

814

815 **Figure 1: Validation of 7G8-specific qPCR covering the full *var* gene repertoire.** (A) The genomic
816 proportion of each *var* gene group in 7G8 parasites. (B) RNA-seq and qPCR expression data shown in a
817 Bland-Altman-Plot where the mean expression of each gene is shown on the X-axis and the ratio
818 between RNA-seq and qPCR values on the y-axis. The mean of all ratios and the confidence interval (CI)
819 of 95% are indicated by lines. Outliers are the two *var1* genes (Pf7G8_020026900, Pf7G8_050037900)
820 and a B-type gene (Pf7G8_060022500), which show higher expression in RNA-seq. (C, D) The RNA
821 sample (cell bank parasites aliquot B, *in vitro* generation 13) analyzed via qPCR (C) or RNA-seq (D) shows
822 a nearly identical expression pattern by both analysis methods. qPCR data show gene expression of each
823 *var* gene relative to the normalizer *arginyl-tRNA synthetase*, RNA-seq data are presented in FPKM
824 (Fragments Per Kilobase of transcripts per Million mapped reads) values. *Var* gene names are listed on
825 the x-axis, *var* group affiliations are indicated in red (group A), dark red (group A, subfamily *var1*), blue
826 (group B), green (group C), yellow (group E, *var2csa*).

827

828 **Figure 2: *Var* transcript profiles of pre-mosquito 7G8 cell bank parasites and of 7G8 parasites recovered**
829 **from infected volunteers on the first day of detectable parasitemia. (A)** Heat map showing individual
830 *var* expression profiles for eleven volunteer samples (M08.1D, M08.2D, M16.1D, M32.1D, M32.2D,
831 M32.3P, M32.4P, M32.5P, C32.1P, C32.2P and C32.3P) taken immediately before the start of treatment
832 and six pre-mosquito cell bank parasite samples (aliquot A: *in vitro* generations 12, 15 and 24 post-thaw;
833 aliquot B: *in vitro* generations 6, 13 and 19 post-thaw). To correct for individual differences in the total
834 *var* expression levels, the expression for each *var* gene was normalized against total *var* expression in
835 each sample. Hierarchical cluster analysis confirmed that pre-mosquito cell bank parasite samples
836 differed from *in vivo* volunteer samples. **(B, C)** Gene expression of each *var* gene and controls relative
837 to the normalizer *arginyl-tRNA synthetase* expression is shown in scatter plots for the pre-mosquito cell
838 bank parasite line **(B)** and parasites obtained from the volunteers **(C)**. Each point represents a value
839 observed for the pre-mosquito samples taken from two independently thawed parasite stocks after 12,
840 15 and 24 (aliquot A) or 6, 13 and 19 parasite generations (aliquot B) and for eleven volunteer samples
841 at day 11–13 after sporozoite inoculation. **(D)** Proportion of *var* gene expression by group for pre-
842 mosquito cell bank parasites and parasites isolated from volunteers. **(E)** Comparison of the expression
843 levels between subtelomeric and centromeric *var* gene variants in pre-mosquito cell bank parasites and
844 parasites isolated from volunteers. Each dot represents the mean relative expression for each *var* gene
845 variant located in either the subtelomeric or centromeric region of the 7G8 genome. Means and
846 standard deviations are given for each group. Statistical analyses were performed using the Mann
847 Whitney U test. **(F)** Heat map of pairwise Pearson correlation coefficients (PCC) between expression
848 profiles illustrates the positive correlation between samples. Group affiliation of *var* genes is indicated
849 by the color code with A-type *var* genes in red, the subfamily *var1* in dark red, B-type genes in blue,
850 group C genes are colored in green and the *var2csa* gene (group E) is shown in yellow. Control genes
851 are shown in black. Annotated pseudogenes are marked with an asterisk. H: housekeeping gene,
852 *fructose-bisphosphate aldolase*; R: ring control, *skeleton-binding protein 1 (sbp1)*.

853

854 **Figure 3: Characterization of parasites expressing Pf7G8_040025600.** (A) Mapping of RNA-seq reads to
855 the locus around the Pf7G8_040025600 gene in cell bank parasite aliquot B (13. *in vitro* generations
856 after thawing). (B) Correct down-regulation of *var* gene expression as the parasite matures from the
857 ring to the schizont stage (cell bank aliquot A). *Var* gene groups are indicated in the middle of the
858 diagrams. (C) Selection of bulk cultures and newly generated subclones on CSA. Parasites obtained from
859 BEI resources (MRA-152) and pre-mosquito cell bank parasites aliquot A (Sanaria A) and eight selected
860 subclones derived from pre-mosquito cell bank aliquot A were enriched for CSA-binding. For each cell
861 line, *var* gene expression is shown at three time points: (i) at the earliest time point after thawing or
862 appearance after cloning (1st), (ii) before (CSA -), and (iii) after (CSA +) CSA selection. As expected from
863 the *var* expression pattern, MRA-152 and the subclone A1G9 bound immediately to CSA due to the high
864 expression of *var2csa* in the population. After three rounds of selection, pre-mosquito cell bank
865 parasites and all other subclones were also enriched for CSA binding and *var2csa* expression. (D)
866 Western blots of pre-selected and CSA-selected parasites using an anti-ATS antibody (6HI) and anti-
867 aldolase as loading control. The truncation of the ATS sequence of 7G8-VAR2CSA hinders recognition of
868 the protein by anti-ATS 6HI, explaining why PfEMP1 signal is lost in all parasite lines after CSA selection.
869 Similarly, MRA-152, A1G9 and A1F4 show no signal due to expression of *var2csa* (MRA-152, A1G9) or
870 the truncated pseudogene Pf7G8_120024200 (A1F4) before selection. *Var* gene names are indicated
871 and annotated pseudogenes are marked with an asterisk, *var* gene groups are colored according to the
872 following scheme: A in red, A-*var1* in dark red, B in blue and C in green.

873
874 **Figure 4: Epigenetic marks at the Pf7G8_040025600 and *var2csa* loci.** (A) Genomic map of *var2csa* and
875 Pf7G8_040025600 (*'varC'*) loci with surrounding open reading frames (ORFs) and transcription start
876 sites (indicated by arrows). The positions of the respective primer pairs used for ChIP-qPCR are indicated
877 by numbers. (B) Chromatin immunoprecipitation with anti-H3K9me3 antibody and quantification of
878 associated gDNA regions of *var2csa* (left panel) and Pf7G8_040025600 loci (right panel) by qPCR (ChIP-
879 qPCR) in pre-mosquito cell bank parasites (aliquot A) from Sanaria (Sanaria A) and the same parasite
880 line enriched for CSA-binding (Sanaria A CSA) (n=1). (C) Levels of gDNA marked with the

881 heterochromatin-associated H3K9me3, the activation mark H3K27ac, or the alternative histone variant
882 H2A.Z associated with active gene expression were determined by ChIP-qPCR at different regions of the
883 *var2csa* (left panels) and Pf7G8_040025600 (right panels) loci in subclones A2E10 (expressing
884 Pf7G8_040025600, '*varC*') and A1G9 (expressing *var2csa*) (n=1). The boundaries of the predicted
885 heterochromatin regions are shaded in B and C. (D) The corresponding expression profiles of *var* genes
886 from RNA obtained in parallel with nuclei for ChIP experiments are shown as pie charts, with *var2csa*
887 and Pf7G8_040025600 colored as indicated and all remaining *var* gene variants colored grey.
888 Summarized total *var* gene expression is indicated for each parasite line.

889

890 **Figure S1: Schematics of the MAVACHE and CVac-Tü3 study designs.**

891

892 **Figure S2: Ranking of *var* genes according to transcript levels detected in samples from malaria-naïve**
893 **volunteers infected with PfSPZ 7G8.** The median *var* transcript level relative to the *arginyl-tRNA*
894 *synthetase* transcript level with IQR is shown for 11 volunteer samples. Group affiliation of *var* genes is
895 indicated by the color code: A-type *var* genes in red, the subfamily *var1* in dark red, B-type genes in blue,
896 group C genes in green, and the *var2csa* gene (group E) in yellow.

897

898 **Figure S3: *Var* gene expression profiles of 7G8 cell bank parasites derived from Sanaria (aliquot A and**
899 **B) and BEI Resources (MRA-152, MRA-926, MRA-154).** (A) Heat map showing *var* expression of 7G8
900 parasites from Sanaria cell bank aliquots A and B and of three 7G8 aliquots deposited at BEI resources
901 by different providers. Expression of each *var* gene is normalized to expression of *arginyl-tRNA*
902 *synthetase*. (B) Pie charts showing the proportion of *var* gene expression by group for the different 7G8
903 lines. The names of *var* genes are indicated, and *var* gene groups are colored according to the scheme:
904 A in red, A-*var1* in dark red, B in blue and C in green.

905

906 **Figure S4: *Var* gene expression profiles of CSA-selected 7G8 cell bank parasites after cultivation for up**
907 **to 100 replication cycles after selection.** Heat map showing the *var* expression of 7G8 cell bank parasites

908 (aliquot A) selected on CSA to express *var2csa* after cultivation for up to 100 parasite replications. The
909 expression of each *var* gene is normalized against the expression of *arginyl-tRNA synthetase*. The names
910 of *var* genes are indicated, and *var* gene groups are colored according to the scheme: A in red, A-*var1*
911 in dark red, B in blue and C in green.

912

913 **Figure S5: qPCR on gDNA from 7G8 subclones to confirm presence of each *var* gene variant in the**
914 **different genomes.** Shown are raw Ct values from about 2.5 ng gDNA used as template per qPCR
915 reaction. The Ct values from the cell bank aliquot A bulk culture are marked in black for reference, and
916 a line is drawn at the mean.

917

918 **Table S1: The 7G8 *var* gene repertoire and the domain composition of the encoding PfEMP1 variants**
919 **according to the classification from Rask *et al.* ⁵.** Question marks indicate unknown features of the *var*
920 gene/PfEMP1. Gene IDs and gene type annotation according to PlasmoDB Release 58 (23. June 2022).
921 ATS: Acidic terminal segment; CIDR: Cysteine-rich interdomain region; DBL: Duffy-binding like domain;
922 NTS: N-Terminal segment; UPS: upstream sequence

923

924 **Table S2: Oligonucleotides used in this study.**

925

926 **Table S3: qPCR data on 7G8 *var* gene expression in pre-mosquito cell bank parasites (A) and in parasites**
927 **from malaria-naïve volunteers (B).**

928

929 **Table S4: *Var* gene expression in MRA-152, 7G8 pre-mosquito cell bank parasites (aliquot A) and 7G8**
930 **subclones before and after CSA selection.**

931


932 **Table S5: Unique genomic variants of 7G8 subclones A1G9 (*var2csa*-expressing subclone, control) versus**
933 **A2G2 and A2E10 (Pf7G8_040025600-expressing subclones) determined by gDNA-seq.**

934

935 Table S6: ChIP-qPCR and *var* expression profiles from 7G8 pre-mosquito cell bank parasites (aliquot A)
936 and 7G8 subclones before and after CSA selection.
937
938 Data S1: All *var* exon 1 sequences used for design of the oligonucleotides and RNA-seq mapping
939 (coding_nt.fa)³⁷.


Table 1: Overview of volunteer characteristics infected with PfSPZ Challenge 7G8 and parasite counts determined either by thick blood smear (TBS) or qPCR at the day of treatment/sampling.

| Volunteer ID | Sex | Year of birth | Immunization | PfSPZ challenge | No. of sporozoites | Day of treatment | Parasites/ μ l (TBS) | Parasites/ml (qPCR) |
|--------------|-----|---------------|-----------------|-----------------|--------------------|------------------|--------------------------|---------------------|
| M08.1D | m | 1976 | dose escalation | 7G8 | 800 | 13 | 11 | 8,216 |
| M08.2D | m | 1988 | dose escalation | 7G8 | 800 | 12 | 7 | 717 |
| M16.1D | m | 1992 | dose escalation | 7G8 | 1,600 | 12 | 30 | 8,593 |
| M32.1D | m | 1989 | dose escalation | 7G8 | 3,200 | 11 | 0 | 3,671 |
| M32.2D | m | 1993 | dose escalation | 7G8 | 3,200 | 12 | 89 | 3,956 |
| M32.3P | f | 1992 | placebo | 7G8 | 3,200 | 10 | 3 | 3,560 |
| M32.4P | f | 1994 | placebo | 7G8 | 3,200 | 11 | 0 | 1,757 |
| M32.5P | m | 1991 | placebo | 7G8 | 3,200 | 11 | 0 | 3,666 |
| C32.1P | f | 1992 | placebo | 7G8 | 3,200 | 11 | 4 | 15,559 |
| C32.2P | m | 1993 | placebo | 7G8 | 3,200 | 10 | 0 | 8,955 |
| C32.3P | m | 1997 | placebo | 7G8 | 3,200 | 11 | 0 | 11,555 |




A


It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




B




C



D



E



F

